Get started
RocketTickers

Esperion Announces FDA Approval of the NEXLIZET™ (bempedoic acid

Long
Esperion Therapeutics, Inc. (NASDAQ:ESPR)  
RocketTickers  
NASDAQ:ESPR   Esperion Therapeutics, Inc.
Beyond Technical Analysis
2
0
beyondta
ESPR: Esperion Therapeutics, Inc.
2020-02-26 17:30:10
Esperion Announces FDA Approval of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.